Cipla shares broke out above ₹1,580–₹1,590 on strong volumes, with technical indicators signaling further gains.

If the deal works out, it would be the largest in the Indian pharma sector, analysts said. Cipla's shares jumped as much as 4.1% after the results and were up 1.9%, as of 3:20 p.m. IST.

Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong ...

The Nifty Pharma Index gained more than 1% amid a weak Indian stock market on a day when the benchmark Nifty 50 Index dipped ...

Cipla's share price experiences a slight decline with a 1.13% drop in weekly returns, despite surpassing its 20-day Simple Moving Average.

Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by ...

India's Torrent Pharmaceuticals is in talks with private equity funds CVC Capital Partners and Bain Capital to raise up to $1.5 billion to bid for India's Cipla, according to three sources with ...

Dr Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, among others, are laying the groundwork for Day 1 ...

Zee Business analysts Ansh Jogendra Bhilwar and Pooja Tripathi have shared a number of calls for trading and investing today, ...

Indian pharma companies will need to change tack and find newer markets should the Trump administration impose a reciprocal tariff on pharma imports ...

As the U.S. gears up to impose a 25% tariff on Indian imports starting August 1, India’s pharmaceutical industry is on alert.

Cipla's shares closed 2.03% higher on Friday after the results. They have risen nearly 17% in the September quarter, outpacing a 12% rise in the Nifty Pharma index (.NIPHARM).